Merck's WINREVAIR™ (sotatercept) receives positive EU CHMP opinion for PAH treatment in adults.
Merck's WINREVAIR™ (sotatercept) receives positive EU CHMP opinion for Pulmonary Arterial Hypertension (PAH) treatment in adults. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends approval of WINREVAIR™ in combination with other PAH therapies. The recommendation is based on promising data from clinical trials.
June 28, 2024
4 Articles